tiprankstipranks
BioNTech (NASDAQ: BNTX) Slides After $0.9 Billion Comirnaty Write-Off
Market News

BioNTech (NASDAQ: BNTX) Slides After $0.9 Billion Comirnaty Write-Off

Story Highlights

BioNTech slid in pre-market trading after announcing inventory write-off charges of $0.9 billion related to COVID-19 vaccine Comirnaty.

Immunotherapy company, BioNTech (NASDAQ: BNTX) slid in pre-market trading on Monday after the company announced the potential impact of Pfizer’s (PFE) write-offs and other charges related to its COVID-19 vaccine, Comirnaty. BioNTech has announced inventory write-off charges of $0.9 billion related to lower-than-anticipated sales of Comirnaty. The company had developed Comirnaty in collaboration with Pfizer.

Pick the best stocks and maximize your portfolio:

BioNTech stated that this write-off will represent the company’s 50% share under its gross profit-sharing agreement with Pfizer. The company anticipates that these charges are likely to drag down its revenues in FY23. BioNTech is expected to release its Q3 results on November 6, 2023.

Is BNTX a Good Stock to Buy?

Analysts are cautiously optimistic about BNTX with a Moderate Buy consensus rating based on three Buys and six Holds. The average BNTX price target of $135.22 implies an upside potential of 30.5% at current levels.

Related Articles
TheFlyPfizer raises quarterly dividend to 43c per share
TheFlyPfizer announces results from PATINA trial
TheFlyNotable open interest changes for December 11th
Go Ad-Free with Our App